alanine/breast neoplasms

Koblingen er lagret på utklippstavlen

Velg sorteringstype

14 resultater

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

1. Test population: Patients with stage III gastric cancer confirmed by postoperative pathology 2. Sample size calculation: single arm design was used in this study, and the main outcome was progression free survival. In this study, PD-L1 + CPS ≥ 10% / MSI-H + / EB +, the sample size was estimated

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

PRIMARY OBJECTIVES: I. To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab?based HER-2 targeted therapy. SECONDARY OBJECTIVES: I. To assess

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab) in comparison to Herceptin® (Genentech/Roche) in patients with Human

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Inclusion criteria: 1. Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques 2. Histologically or cytologically confirmed tumor 3. Age of 18 years or more 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 5. Patients have failed,

Ribociclib and Bicalutamide in AR+ TNBC

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OUTLINE: This is a multi-center study. INVESTIGATIONAL TREATMENT: - bicalutamide - 150mg po daily D1 - D28 (Cycle = 28 days) - ribociclib po daily D1 - D21 of 28 day cycle PHASE I SAFETY RUN-IN COHORT: The maximum tolerated dose (MTD) of bicalutamide in combination with ribociclib will be determined

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

The FG-3019 treatment will be administered over a 28-day cycle: - Dose: 35 mg/kg - Route: IV over one hour following completion of gemcitabine infusion - Schedule: - Days 1, 8, and 15 - Please note that Day 8 infusion will on be completed during the first treatment cycle On Drug Evaluation The

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

1. Introduction to investigational treatment(s) and other study treatment(s) 1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OUTLINE: This is a multi-center trial. INVESTIGATIONAL TREATMENT: - Palbociclib 125 mg will be administered orally once daily on days 1-21 (D1-D21) of each 28-day cycle. Subjects will not take palbociclib on D22-D28. - Tamoxifen 20 mg will be administered orally once daily for every day of the

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OUTLINE: This is a multi-center trial. SEQUENCING: DNA from archived tumor samples collected at the time of surgery (residual disease post neoadjuvant chemotherapy) will be extracted and sequenced. The resulting sequencing data will be interrogated for known genomic drivers of sensitivity or

Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the leading causes of mortality and morbidity in the intensive care unit (ICU). The causes of ALI/ARDS differ from patient to patient, including sepsis, aspiration, systemic inflammation, trauma, blood transfusion, etc. With

Physician Liver Function Test (LFT) Monitoring for Tykerb Pts

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OUTLINE: This is a multi-center study. Safety Run-in will be for the first 12 patients on study only (6 in cohort 1 and 6 in cohort 2). Patients in the safety run will be included in the efficacy analysis on intent to treat basis: Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg

Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Head and neck squamous cell carcinoma (HNSCC) (excluding nasopharyngeal cancer) accounts for 4% to 5% of the cancer incidence in Taiwan.1 Localized disease is curable by surgery and irradiation. Two-thirds of patients present with advanced stages of the disease (stage III and IV), and are treated

Lonafarnib in Metastatic Breast Cancer

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OUTLINE: This is a multi-center study Patients will be treated with lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion. 1 Cycle = 21 days of lonafarnib (plus the time required to recover from toxicity if

Bli med på
facebooksiden vår

Herbal & Natural Medicine

Den mest komplette databasen med medisinske urter støttet av vitenskap

Fungerer på 55 språk
Urtekurer støttet av vitenskap
Urtegjenkjenning etter bilde
Interaktivt GPS-kart - merk urter på stedet (kommer snart)
Les vitenskapelige publikasjoner relatert til søket ditt
Søk medisinske urter etter deres effekter
Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter

Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning